



## INSILICO DESIGN, SYNTHESIS, AND ANTHELMINTIC ACTIVITY SCREENING OF SOME 6-BENZIMIDAZOYL PYRANS

**Madhu C. Divakar<sup>1\*</sup> and Francis M. Saleshier<sup>2</sup>**

<sup>1</sup>Department of Pharmacognosy and Phytochemistry, PPG College of Pharmacy, Saravanampatti, Coimbatore, India 641035.

<sup>2</sup>Department of Pharmaceutical Chemistry, SriRamakrishna College of Pharmacy, SRIPMS, Coimbatore, Tamil Nadu, India.

**\*Corresponding Author: Dr. Madhu C. Divakar**

Department of Pharmacognosy and Phytochemistry, PPG College of Pharmacy, Saravanampatti, Coimbatore, India 641035.

Article Received on 25/10/2022

Article Revised on 15/11/2022

Article Accepted on 05/12/2022

### ABSTRACT

An extension of our research for novel anthelmintic agents, some hybrid derivatives containing C-2 pyran of benzimidazole were made by Michael condensation of ethyl cyano acetate in presence of pyridine. Molecular docking studies were then used to find the structural prerequisites for activity of this series of compounds. Whip worms were used in the study to screen the anthelmintic activity of the compounds synthesized. The results indicated that, all the compounds were found to be moderately effective against whip worm (*Trichuris trichuria*) at 1 and 2 mg/ml compared to the standard reference drug mebendazole. The benzimidazole pyran analogue's percentage yield obtained was found to be in the array of 55-79. The molecular docking studies revealed that, the compounds 1 & 3 showed good binding affinity with  $\beta$ -tubulin receptors.

### INTRODUCTION

Following the discovery of thiabendazole in 1961, several benzimidazoles are introduced afterwards as broad spectrum anthelmintics. The imidazole or imidazoline with benzene moiety are termed as benzimidazole. Benzimidazoles are found to be effective against intestinal round worms. Benzimidazole ring system<sup>[1,2,3,4,5]</sup> can be seen commonly in different classes of therapeutically effective synthetic drugs. Normally the characteristics of the drugs may vary from one to the other in terms of the substitutions to the basic moiety at 1, 2, or 5 positions.<sup>[6]</sup> Usually anthelmintic drugs contain 2 and 5 substituted benzimidazole ring systems.<sup>[7, 8]</sup> Large substitutions at 1, and 2 positions can be observed in antihistamines (H1).<sup>[10]</sup> Proton pump inhibitors have large substituent groups at position 2 of benzimidazole ring system.<sup>[9]</sup>

The N-ribosyl – dimethyl benzimidazole which serves as an axial ligand for cobalt in vitamin B<sub>12</sub> is considered as a noticeable benzimidazole compound in nature.<sup>[11]</sup> Reports<sup>[12]</sup> on benzimidazole includes in the fused heterocyclic system normally associated with diverse pharmaceutical activities showed that on pyridine ring substitution by electron donating groups increase the activity of the parent compound.

Anthelmintic drugs are used generally to treat worm infestations from flat worms, (fluke worms, tapeworms etc.) and round worms (hook worms, whip worm, ring worms, pin worms etc.).<sup>[13,14]</sup> As per WHO<sup>[15]</sup> about 2

billion people are suffering from parasitic worm infections round the world. The livestock and crops also diseased by the parasitic worms which may end up in an economic impact. Yet, the majority of drugs are limited in their action, e.g., praziquantel, a drug used in the treatment of schistosomiasis has no activity against other round worms.

Satyavan Sharma et al<sup>[16]</sup> synthesized 5 substituted 2 alkyl /aryl –carbonyl amino benzimidazoles. These compounds showed 74-100% reduction of microfilariae and adult filarial worm, *Litomosoides carini*. C.V Reddy & Sastry et al<sup>[17]</sup> synthesized a series of methyl 5, 6 -3 -oxo -1, 4 benzo thiazin – 7-glyoxyl] benzimidazole – 2-carbamates and screened for their anthelmintic activity. M.Himaja Rajiv et al<sup>[22]</sup> synthesized 6-nitro benzimidazole-1-acetyl-amino acids and peptides and observed the highly potent activity of these compounds against nematodes.

Benzimidazoles exerts their anthelmintic activity<sup>[18,19]</sup> by the selective inhibition of  $\beta$ - tubulin (a receptor protein) polymerization thereby suppressing the cellular transport and energy metabolism in the worm cells. Again, benzimidazoles gradually exhaust the energy reserves and obstruct the excretion of waste products from parasitic cells. Slight structural alteration of the beta tubulin receptor in the resistant organism results in lowering of the binding affinity of benzimidazoles, finally results in cross resistance. Many studies<sup>[20,21]</sup>

showed that beta tubulin substituted with a single amino acid result in anthelmintic drug resistance.

The whip worm (*Trichuris trichuria*) was estimated to infect 750 million people throughout the world, chiefly in the tropics. Man becomes infected by ingesting contaminated soil, food, or water containing infective *Trichuris* eggs previously passed in faeces. The lifetime of the adult *Trichuris* is normally a year. Sigmoidoscopy is the diagnosis tool for finding trichuris eggs or the adult worms in stool.

In the present study, likely derivatives of benzimidazole pyran compounds were predicted and docked by using  $\beta$  tubulin (Protein Data Bank id TUBB 5). The *insilco* molecular study of these all these predicted compounds are found to obey "Lipinski rule of five". Autodock 4.2, Cygwin and Schrodinger software were used to predict the anthelmintic activity for the selected derivatives. *Molinspiration* (online server) was used to evaluate the molecular properties of the compounds selected. The compounds with high glide score are considered for synthesis as per our earlier communication.<sup>[26]</sup>

## MATERIALS AND METHODS

All the chemicals were obtained from Loba Cheme, S.D. Fine Chem, Himedia (for substituted ketones), Sigma (for substituted benzaldehydes) and Hayman Ltd (for ethanol).

The UV and IR spectra of the synthesized derivatives were documented<sup>26</sup> on JASCO V 530 UV/VIS spectrophotometer and JASCO FT/IR-410 at the Department of Pharmaceutical analysis, SRIPMS, Coimbatore, India. Finnegan MAT 8230 at Indian Institute of Technology, Chennai was utilized for recording the Mass spectra of the prepared compounds. The PMR spectra of the compounds were recorded on Burker 200 MHz at the Dept. of Chemistry, Bharathidasan University, Trichy. The melting points of all the prepared derivatives were taken and uncorrected using melting point apparatus MP-DS, TID 2000.

### Outline of synthesis -1

#### Stage-1

*Synthesis of 2-( $\alpha$ -hydroxyl ethyl) benzimidazole:*

The reaction mixture contains 27 g (0.25mol) of o-phenylene diamine, 25.5ml (30.6g, 0.34 mol) of lactic acid which was refluxed for around 3h, cooled and made alkaline by the slow addition of sodium hydroxide (10%) solution. The final product obtained was dissolved in 400

ml of boiling water, and digested with 2 g of activated charcoal for 15 min. The final solution was filtered using a Buchner funnel, and the filtrate was cooled to around 10°C. The product was again washed with 25 -30 ml of cold water and dried at 100°C in a desiccator.

#### Stage-2

*Synthesis of 2-acetyl benzimidazole:*

The compound obtained from step -1 (5 mmoles) was added to a ground mixture of  $\text{KMnO}_4$  (2g, 12.65 mmoles) and solid neutral alumina (2.5 g). Then acetone (20ml) was added to the reaction mixture with forceful stirring and the filtrate was evaporated and the crude residue was taken up in chloroform (15ml) and washed with water (30ml) in order to remove inorganic matter and dried using anhydrous sodium sulfate. Hot water was used to recrystallize the final product as needle like crystals.

#### Stage-3


*Synthesis of chalcones<sup>[25]</sup>*


The compound obtained from stage-2 (20 mmoles) and sodium hydroxide (4 g, 100mmoles) were mixed thoroughly to a fine powder at room temperature. Different aromatic aldehydes (30mmoles) were added to the mixture and stirred well at room temperature for a 5-10 min. until the condensation was over. The solid residue was washed with water to remove inorganic impurities and dried.

#### Stage-4

*Synthesis of pyrans*

A mixture of chalcones (0.01mole) and ethyl cyano acetate (0.01mol) in pyridine was treated for 48h, cooled and decanted in water. The solid residue obtained was recrystallized from  $\text{CHCl}_3$ -Pet.ether mixture (1:2).





Aromatic aldehyde  
(30mmoles)


0.01mol 1-(1H-benzimidazol-2-yl)-3-[4-(dimethylamino) phenyl]prop-2-en-1-one

Ethyl-2-amino-6-(1H-benzimidazol-2-yl)-4-Phenyl-4H-Pyran-3-Carboxylate


### Outline of synthesis - 2

This stage explains the reaction of chalcones with ethyl cyanoacetate in pyridine for the development of the pyran ring system in the mixture.

#### Stage-1



#### Stage 2



| Compound | R <sup>1</sup>   | R <sup>2</sup>   | Molecular formula  | Melting point | %yield | Rf value | Molecular weight |
|----------|------------------|------------------|--|---------------|--------|----------|------------------|
| C-1      | H                | H                | C <sub>21</sub> H <sub>19</sub> N <sub>3</sub> O <sub>3</sub>    | 204.5         | 59     | 0.57     | 361.4            |
| C-2      | Cl               | H                | C <sub>21</sub> H <sub>18</sub> N <sub>3</sub> O <sub>3</sub> Cl | 211.0         | 65     | 0.74     | 395.8            |
| C-3      | H                | OCH <sub>3</sub> | C <sub>22</sub> H <sub>21</sub> N <sub>3</sub> O <sub>4</sub>    | 231.5         | 78.3   | 0.55     | 391.4            |
| C-4      | OCH <sub>3</sub> | H                | C <sub>22</sub> H <sub>21</sub> N <sub>3</sub> O <sub>4</sub>    | 219.0         | 70.5   | 0.61     | 391.4            |
| C-5      | NO <sub>2</sub>  | H                | C <sub>21</sub> H <sub>18</sub> N <sub>4</sub> O <sub>5</sub>    | 236.0         | 64.5   | 0.67     | 406.4            |

The spectral, chromatographic, and elemental analysis of the compounds selected for synthesis were compared with the previously reported<sup>26</sup> physical and spectral data by the authors and compared the similarity for all the synthesized compounds. Compound -1(C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>,

m.p.:204-205<sup>0</sup>C), Compound-2 (C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub>Cl, m.p.:210-212<sup>0</sup>C), Compound-3(C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>, m.p.:210-212<sup>0</sup>C), Compound-4 (C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub>, m.p.:218-220<sup>0</sup>C), Compound -5 (C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub>, m.p.:235-237<sup>0</sup>C).


**Invitro anthelmintic activity screening<sup>[23]</sup>**

Live whip worms were collected in 0.9 % physiological saline from the pigs slaughtered at local abattoirs. After through washing in physiological saline, the worms were maintained in climatic chamber at  $37.0 \pm 1^\circ\text{C}$ . Each concentration (five synthesized compounds) of compounds synthesized was tested against single batch of six worms that are maintained separately in ten petridishes containing 45 ml of medium. Dilutions of compounds were made in dimethyl sulfoxide. Diluted compound was added to the medium to give 1, 2 mg/ml concentration. Mebex, a broad spectrum anthelmintic was used as reference drug. The latter was also dissolved in DMSO and tested at similar to those of synthesized compounds.


For each such concentration one petridish containing 5 ml of DMSO on the medium served as a control. The experiments were repeated for two times. The efficacy of the synthesized compounds was evaluated in terms of the motility and histomorphological changes of the worms. The time taken for complete paralysis of the worms were recorded and death was confirmed by dipping the worms in warm water. Soon after the worms got paralyzed, a set of those treated with 2 mg/ml of drug along with the ones of controls were picked up and fixed in formalin were subjected to scanning light microscopy studies by standard techniques.

| No | Compound code              | Paralysis ( in h )   |                      |
|----|----------------------------|----------------------|----------------------|
|    |                            | Concentration 1mg/ml | Concentration 2mg/ml |
| 1  | C-1                        | 10-12                | 8-10                 |
| 2  | C-2                        | 12-13                | 10-12                |
| 3  | C-3                        | 11-15                | 9-11                 |
| 4  | C-4                        | 14-16                | 10-12                |
| 5  | C-5                        | 13-15                | 10-13                |
| 6  | Standard drug: Mebendazole | 4-6                  | 2-4                  |


*Worms incubated in control medium showed physical activity till 54 to 68 hours.*




**T.S of normal whip worm**



**T.S of mebendazole treated worm**



**T.S of worm treated with C-1**



**T.S of worm treated with C-2**



**T.S of worm treated with C-3**



**T.S of worm treated with C-4**



**T.S of worm treated with C-5**









**Whip worm**



**Egg of whip worm**

Photomicrograph of the T.S of the whip worm of different drug treated groups, standard drug treated and control

**Compound 1 2, 3, 4 and 5****Compound 1****Compound 2****Compound 3****Compound 4****Compound 5**

The impulsive photos of the docked compounds with  $\beta$ -tubulin (with high binding energy) showing the binding sites

**Table 2: The predicted glide scores of the different benzimidazole pyran derivatives.**

| Compound | Chemical name   | Glide score |
|----------|---|-------------|
| C-1      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-phenyl-4H-pyran-3-carboxylate            | -6.092395   |
| C-2      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-chlorophenyl)-4H-pyran-3-carboxylate  | -4.927417   |
| C-3      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-methoxyphenyl)-4H-pyran-3-carboxylate | -6.032163   |
| C-4      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-methoxyphenyl)-4H-pyran-3-carboxylate | -5.533157   |
| C-5      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-nitrophenyl)-4H-pyran-3-carboxylate   | -5.888931   |
| C-6      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-chlorophenyl)-4H-pyran-3-carboxylate  | -5.853321   |
| C-7      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-chlorophenyl)-4H-pyran-3-carboxylate  | -5.832231   |
| C-8      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-methoxyphenyl)-4H-pyran-3-carboxylate | -5.653202   |
| C-9      | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-nitrophenyl)-4H-pyran-3-carboxylate   | -4.544211   |
| C-10     | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-nitrophenyl)-4H-pyran-3-carboxylate   | -4.552231   |
| C-11     | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-bromophenyl)-4H-pyran-3-carboxylate   | -5.7544225  |
| C-12     | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-bromophenyl)-4H-pyran-3-carboxylate   | -5.6745322  |
| C-13     | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-bromophenyl)-4H-pyran-3-carboxylate   | -5.556734   |

|      |   |             |
|------|---|-------------|
| C-14 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-methylphenyl)-4H-pyran-3-carboxylate  | -4.234542   |
| C-15 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-methylphenyl)-4H-pyran-3-carboxylate  | -4.185443   |
| C-16 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-methylphenyl)-4H-pyran-3-carboxylate  | -4.2045331  |
| C-17 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-fluorophenyl)-4H-pyran-3-carboxylate  | -5.6725522  |
| C-18 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-fluorophenyl)-4H-pyran-3-carboxylate  | -5.5654434  |
| C-19 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-fluorophenyl)-4H-pyran-3-carboxylate  | -5.6433111  |
| C-20 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-ethoxy phenyl)-4H-pyran-3-carboxylate | -5.0845542  |
| C-21 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-ethoxy phenyl)-4H-pyran-3-carboxylate | -5.2333511  |
| C-22 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-ethoxy phenyl)-4H-pyran-3-carboxylate | -5.2114544  |
| C-23 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(2-hydroxyphenyl)-4H-pyran-3-carboxylate | -5.2054435  |
| C-24 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(3-hydroxyphenyl)-4H-pyran-3-carboxylate | -5.19335421 |
| C-25 | ethyl 2-amino-6-(1H-benzimidazol-2-yl)-4-(4-hydroxyphenyl)-4H-pyran-3-carboxylate | -5.1877556  |

Benzimidazole compounds are structurally similar to naturally occurring nucleotides therefore they interact easily with the biological system.<sup>[24]</sup> Anthelmintics with broad spectrum of activity are found effective against parasitic flat worms and round worms.<sup>[25]</sup>

The current work targeted mainly on the design and progress of benzimidazole pyran derivatives as anthelmintic drugs with preliminary *insilico* screening of various derivatives. The data showed that, all the compounds were found to be moderately active against *Trichuris trichuria* (whip worm) at 1 and 2 mg/ml compared to the standard reference - mebendazole. The yield of all the benzimidazole pyran derivatives were found to be in the range of 55-79%. The pyran with unsubstituted phenyl grouping took only less time for immobilization of whip worms as compared to substituted phenyl derivatives.

The compound-1 and compound-3, showed good binding affinity with tubulin receptors, (glide score: -6.092395 and -6.032163), in the docking studies. These values were in good match with the invitro anthelmintic activity reports for the real-time synthesized compounds.

#### ACKNOWLEDGEMENT

The authors were thankful to Bioinformatics Facility, Rajiv Gandhi Center for Biotechnology, Thiruvananthapuram, Kerala for their help extended to us during the docking studies.

#### REFERENCES

1. J. Velik, V. Baliharova, J. Fink. Benzimidazole drugs and modulation of biotransformation enzymes Res.Vet. Sci., 2004; 756: 95.
2. V. K. Pandey, Z. Tusi, S. Tusi, M. N. Joshi and S. K. Bajpai. Synthesis of 8-(aralkyl amido/imido) - 7-hydroxy-4-methyl quinolinyl\_1,5-c- benzimidazoles as potential antiviral compounds, Indian J. Het. Chem., 2002; 111: 309-312.
3. Sawhney SN, et al. Synthesis and anti-inflammatory activity of some 2-(5-aryl-4-5-dihydropyrazol-3-yl) - and 2-(2-amino-6-arylpyrimidin-4-yl) benzimidazoles. Indian Journal of Chemistry, 1990; 29B: 1107-1112.
4. M. J. Kornet, W. Beaven and T. Varia Synthesis and anticonvulsant evaluation of 1-amino-1, 3-dihydro-2H-benzimidazol-2-ones. J. Heter.Chem., 1985; 22: 1089.
5. Pratibha Sharma, Anupam Mandloi and Shreeya Pritmani. "Synthesis of new 2-(substituted benzothiazolyl carbamoyl) Benzimidazole as potential CNS depressants". Indian Journal of Chemistry, November, 1999; 38B: 289- 1294.
6. Bochis RJ, Olen LE, Fisher MH, Reamer RA. Isomeric phenylthioimidazo [1, 2-a] pyridines as anthelmintics. Journal of Medicinal Chemistry, 1981; 24: 1483-1487.
7. Haugwitz RD, Maurer BV, Jacobs GA, Narayanan VL, Antiparasitic agents. 3. Synthesis and anthelmintic activities of novel 2-P yridinyl-5-isothiocyanatobenzimidazoles. Journal of Medicinal Chemistry, 1979; 22(9): 1113-1118.
8. J. Martin, O. Meth.cohn, H. Suschitzky, A simple route to polychloro benzimidazoles and related systems Tetrahedron letters, 1973; 4495.
9. J.C.Sih, W.B.Im, A.Robert, D.R.Grabber, D.P. Blackmann, Studies on (H<sup>+</sup>-K<sup>+</sup>)-ATPase Inhibitors of Gastric acid Secretion. Prodrugs of 2-[(2-Pyridinylmethyl) sulfinyl] benzimidazole Proton-Pump Inhibitors," Journal of Medical Chemistry, Vol. 34, No. 3, 1991, pp. 1049- 1062. J.Med. Chem., 1991; 34: 1049-1062.
10. Fatma A. Bassyouni, Tamer S. Saleh, Mahmoud M. ElHefnawi etc., Synthesis, pharmacological activity evaluation and molecular modeling of new polynuclear heterocyclic compounds containing benzimidazole derivatives. Arch Pharm Res., 2012; 35(12): 2063-2075.
11. Barker H.A, Sayth R.D, Weissbach H., Toohey J.I., Ladd J.N, Volkani. B.E.Isolation and properties of crystalline cobamide coenzymes containing benzimidazole or 5, 6-dimethylbenzimidazole. J. Biol. Chem., 1960; 235(2): 480-488.
12. Grassi.A, Ippen.J, Bruno.M, Thomas.G, and Bey.P, BAY P 1455, a thiazolyl aminobenzimidazole derivative with gastro protective properties in the rat.Eur. J. Pharmacol, 1991; 195(2): 251-9.
13. Arjmand F, Mohani. B, Ahmad.S, Synthesis, antibacterial, antifungal activity and interaction of CT-DNA with a new benzimidazole derived Cu (II) complex. Eur.J.Med.Chem., 2005; 40(11): 1103-1110.

14. Spason A, Yozhitsu L, Bugaeva I, and Anisimova VA. Benzimidazole derivatives: Spectrum of pharmacological activity and toxicological properties (a review), *Pharmaceutical Chemistry Journal*, 1999; 33(5): 232-243.
15. Controlling disease due to helminth infections. Crompton DWT, Montresor A, Nesheim MC, Savioli L. Strategy Development and Monitoring for Parasitic Diseases and Vector Control, Prevention and Eradication World Health Organization, Geneva, Switzerland, 2003.
16. Shawkat Naim S, Sudhir K Singh and Satyavan Sharma, Suman Gupta, Khan AM, Chatterjee KK, Katiyar JC. "Studies in antiparasitic agents. Part II. Synthesis of 5-substituted 2-alkyl (aryl) carbonyl amino benzimidazoles as orally effective anthelmintics", *Indian J. Chem., Sect. B.*, 1990; 29B(5): 464-470.
17. Shastri CVR, Kondaiah K and Sai GST. Synthesis and anthelmintic activity of [5(6) (3-oxo-1, 4-benzothiazin-7yl-oxy)-benzimidazole]2-carbamates. *Indian J Chem.*, 1990; 29B: 297-299.
18. Friedman PA, Platzer EG. Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. *Biochim Biophys Acta.*, 1978; 544: 605-614.
19. Lubega GW, Prichard RK. Specific interaction of benzimidazole anthelmintics with tubulin: high-affinity binding and benzimidazole resistance in *Haemonchus contortus*. *Mol Biochem Parasitol*, 1990; 38: 221-232.
20. Kwa MSG, Veenstra JG, Roos MH. Molecular characterizations of  $\beta$ -tubulin genes present in benzimidazole-resistant populations of *Haemonchus contortus*. *Mol Biochem Parasitol.*, 1993; 60: 33-144.
21. Driscoll M, Dean E, Reilly E, Bergholz E, Chalfie M. Genetic and molecular analysis of a *Caenorhabditis elegans* beta tubulin that conveys benzimidazole sensitivity. *J Cell Biol.*, 1989; 109: 2993-3003.
22. M.Himaja Rajiv and MV Ramana, Synthesis of some 6-nitro benzimidazole-1-acetyl-amino acids and peptides. *Indian J.Hetero.Chem.*, 2002; 12: 121-124.
23. Yadav, A. K., Tandon, V. & Rao, H. S. P. In Vitro Anthelmintic Activity of Root-Tuber's Extract of *Flemingia vestita* against *Ascaris suum*. *Fitoterapia*, 1992; LXIII: 395-398.
24. A.T.S. Mavrova, K.K. Anichina & D.I. Vuchev. Synthesis and anti - trichinellosis activity of some 2-substituted-[1, 3] thiazolo [3, 2-a] benzimidazol-3(2H)-ones. *Bioorg. Med. Chem.*, 2005; 13: 5550.
25. Jongsuksuntigul P, Jeradit C, Pornpattanakul S, Charanasri U. Comparative study of albendazole and mebendazole in the treatment of ascariasis, hookworm infections and trichuriasis. *Southeast Asian Journal of Tropical Medicine and Public Health*, 1991; 24: 724-729.
26. Francis M Saleshier, Suresh.S1, Anitha. N, JubinaKarim and Madhu.C. Divakar. Design, docking and synthesis of some 6-benzimidazolyl pyrans and screening of their anti-tubercular activity. *European Journal of Experimental Biology*, 2011; 1(2): 150-159.